BioSpace News Archive

Capricor Therapeutics announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd. and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering.

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two poster presentations reporting positive data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego, CA.

Structure Therapeutics Inc. announced positive results from the Phase 1b multiple ascending dose study of its highly selective oral GLP-1 receptor agonist, GSBR-1290, in healthy overweight or obese individuals.

Structure Therapeutics Inc. announced it has entered into a share purchase agreement for the sale of 21,617,295 ordinary shares and 2,401,920 newly designated non-voting ordinary shares at $12.49 per share through a private placement financing.

JCR Pharmaceuticals Co., Ltd. announced key results from the 52-week interim data of its global phase I/II study with JR-171 in individuals with mucopolysaccharidosis type I.

Portage Biotech Inc. announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,157,895 shares of its common stock, at a purchase price of $1.90 per share.

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, will release its third quarter 2023 financial results before the market opens on Friday, October 27, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results.

On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/09995.HK) to advance the development of Akeso’s globally first PD-1/CTLA-4 bispecific antibody, cadonilimab (trade name: 开坦尼®), and RemeGen’s first domestically developed antibody-drug conjugate (ADC) injection,

Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.

Hepion Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase and sale of 980,393 shares of its common stock at a purchase price of $5.10 per share in a registered direct offering priced at-the-market under Nasdaq rules.